Buprenorphine-naloxone for Opioid use disorder
Inspect the conclusion, its exact scope, the statements used to support it, and when each source was checked. This page does not add clinical advice or extend the published research beyond its stated scope.
Published assessment
Only this Treatment × Need pair is assessed here.
Research suggests benefit in this exact scope
Published Aug 31, 2026 · revision 11
Reasoning and support
Open any source row to inspect scope and supporting text.
conclusion
The retained SAMHSA guidance supports buprenorphine treatment for opioid use disorder while preserving product, personal-suitability, and access boundaries.
SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 31, 2026
Relationship source
Why this Treatment appears in the Need landscape, separate from the research conclusion.
SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 30, 2026
Relationship: medication treatment for opioid use disorder
Scope: country:US
Pointer: /conclusion
Open sourceSee something wrong? Tell us. Your note is private. We check sources before we change this page.